“Cancer is not a defined or fixed entity. Cancer evolves, grows and changes over time, which means effective treatments need to be able to respond in kind. They cannot be stationary or limited in scope. They must be able to adapt to the changing landscape of cancer.”
E. Antonio Chiocca, MD, PhD
Brigham and Women’s Hospital
Since its founding, Alliance for Cancer Gene Therapy has quickly become a catalytic force in shaping entirely novel approaches to curing cancer by identifying, funding, and advancing the most innovative and impactful translational research in cell and gene therapies; effective, efficient, less toxic cancer therapies that use the body’s own cells and genes as medicine.
As we build alliances, fund new research, and see innovative therapeutic approaches move through clinical trials, we are enabling immunotherapy experts to join forces with cancer cell biology experts to change the outlook for cancer patients.
An ambitious collaboration between Alliance for Cancer Gene Therapy, Cancer Research Institute and Parker Institute for Cancer Immunotherapy is tackling the challenges of the deadliest brain cancer in adults – glioblastoma multiforme (GBM) – and accelerating cellular therapies to battle this complex disease.
